DOI QR코드

DOI QR Code

Comprehensive Assessment of Associations between ERCC2 Lys751Gln/Asp312Asn Polymorphisms and Risk of Non-Hodgkin Lymphoma

  • Zhou, Jue-Yu (Institute of Genetic Engineering, Southern Medical University) ;
  • He, Li-Wen (Institute of Genetic Engineering, Southern Medical University) ;
  • Liu, Jie (Department of Gynaecology and Obstetrics, Nanfang Hospital, Southern Medical University) ;
  • Yu, Hai-Lang (Institute of Genetic Engineering, Southern Medical University) ;
  • Wei, Min (Institute of Genetic Engineering, Southern Medical University) ;
  • Ma, Wen-Li (Institute of Genetic Engineering, Southern Medical University) ;
  • Shi, Rong (Institute of Genetic Engineering, Southern Medical University)
  • 발행 : 2014.11.28

초록

Background: Excision repair crossing-complementing group 2 (ERCC2), also called xeroderma pigmentosum complementary group D (XPD), plays a crucial role in the nucleotide excision repair (NER) pathway. Previous epidemiological studies have reported associations between ERCC2 polymorphisms and non-Hodgkin lymphoma (NHL) risk, but the results have remained controversial. Materials and Methods: We conducted this meta-analysis based on eligible case-control studies to investigate the role of two ERCC2 polymorphisms (Lys751Gln and Asp312Asn) in determining susceptibility to NHL. Ten case-control studies from several electronic databases were included in our study up to August 14, 2014. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using fixed- or random-effects models to estimate the association strength. Results: The combined results based on all studies did not show any association between Lys751Gln/Asp312Asn polymorphisms and NHL risk for all genetic models. Stratified analyses by histological subtype and ethnicity did not indicate any significant association between Lys751Gln polymorphism and NHL risk. However, a significant reduced risk of NHL was found among population-based studies (Lys/Gln versus Lys/Lys: OR=0.87, 95% CI=0.77-0.99, P=0.037) but not hospital-based studies. As for Asp312Asn polymorphism, there was no evidence for the association between this polymorphism and the risk of NHL in all subgroup analyses. Conclusions: This meta-analysis suggests that there may be no association between Lys751Gln/Asp312Asn polymorphism and the risk of NHL and its two subtypes, whereas ERCC2 Lys751Gln heterozygote genotype may provide protective effects against the risk of NHL in population-based studies. Therefore, large-scale and well-designed studies are needed to clarify the effects of haplotypes, gene-gene, and gene-environment interactions on these polymorphisms and the risk of NHL and its different histological subtypes in an ethnicity specific population.

키워드

참고문헌

  1. Baris S, Celkan T, Batar B, et al (2009). Association between genetic polymorphism in DNA repair genes and risk of B-cell lymphoma. Pediatr Hematol Oncol, 26, 467-72. https://doi.org/10.3109/08880010903096201
  2. Benhamou S, Sarasin A (2002). ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis, 17, 463-9. https://doi.org/10.1093/mutage/17.6.463
  3. Berwick M, Vineis P (2000). Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst, 92, 874-97. https://doi.org/10.1093/jnci/92.11.874
  4. Chiu BC, Weisenburger DD, Zahm SH, et al (2004). Agricultural pesticide use, familial cancer, and risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev, 13, 525-31.
  5. Cochran W (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29. https://doi.org/10.2307/3001666
  6. de Boer J, Hoeijmakers JH (2000). Nucleotide excision repair and human syndromes. Carcinogenesis, 21, 453-60. https://doi.org/10.1093/carcin/21.3.453
  7. De Silva IU, McHugh PJ, Clingen PH, et al (2000). Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol, 20, 7980-90. https://doi.org/10.1128/MCB.20.21.7980-7990.2000
  8. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  9. Duan XL, Gong H, Zeng XT, et al (2012). Association between XPD Asp312Asn polymorphism and esophageal cancer susceptibility: a meta-analysis. Asian Pac J Cancer Prev, 13, 3299-303. https://doi.org/10.7314/APJCP.2012.13.7.3299
  10. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  11. El-Din MA, Khorshied MM, El-Saadany ZA, et al (2013). Excision repair cross-complementing group 2/Xeroderma pigmentousm complementation group D (ERCC2/XPD) genetic variations and susceptibility to diffuse large B cell lymphoma in Egypt. Int J Hematol, 98, 681-6. https://doi.org/10.1007/s12185-013-1462-1
  12. Evans E, Moggs JG, Hwang JR, et al (1997). Mechanism of open complex and dual incision formation by human nucleotide excision repair factors. EMBO J, 16, 6559-73. https://doi.org/10.1093/emboj/16.21.6559
  13. Fabisiewicz A, Pacholewicz K, Paszkiewicz-Kozik E, et al (2013). Polymorphisms of DNA repair and oxidative stress genes in B-cell lymphoma patients. Biomed Rep, 1, 151-5.
  14. Friedberg EC (2001). How nucleotide excision repair protects against cancer. Nat Rev Cancer, 1, 22-33. https://doi.org/10.1038/35094000
  15. Gillet LC, Scharer OD (2006). Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem Rev, 106, 253-76. https://doi.org/10.1021/cr040483f
  16. Grulich AE, Vajdic CM, Cozen W (2007). Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev, 16, 405-8. https://doi.org/10.1158/1055-9965.EPI-06-1070
  17. Hartge PWS (2004). Overview of the etiology and epidemiology of lymphoma. In: Mauch PM, Armitage JO, Coiffier B, et al. (eds). Non-Hodgkin's Lymphomas. Lippincott Williams and Wilkins, New York, NY, pp711-27.
  18. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. https://doi.org/10.1136/bmj.327.7414.557
  19. Huang LM, Shi X, Yan DF, et al (2014). Association between ERCC2 polymorphisms and glioma risk: a meta-analysis. Asian Pac J Cancer Prev, 15, 4417-22. https://doi.org/10.7314/APJCP.2014.15.11.4417
  20. Itin PH, Sarasin A, Pittelkow MR (2001). Trichothiodystrophy: update on the sulfur-deficient brittle hair syndromes. J Am Acad Dermatol, 44, 891-920. https://doi.org/10.1067/mjd.2001.114294
  21. Kim HN, Kim NY, Yu L, et al (2014). Polymorphisms in DNA repair genes and MDR1 and the risk for non-Hodgkin lymphoma. Int J Mol Sci, 15, 6703-16. https://doi.org/10.3390/ijms15046703
  22. Li SX, Dai QS, Chen SX, et al (2014). Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis. Tumour Biol, 35, 3905-15. https://doi.org/10.1007/s13277-013-1519-z
  23. Liu D, Wu D, Li H, et al (2014). The effect of XPD/ERCC2 Lys751Gln polymorphism on acute leukemia risk: a systematic review and meta-analysis. Gene, 538, 209-16. https://doi.org/10.1016/j.gene.2014.01.049
  24. Lunn RM, Helzlsouer KJ, Parshad R, et al (2000). XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis, 21, 551-5. https://doi.org/10.1093/carcin/21.4.551
  25. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  26. Shen M, Purdue MP, Kricker A, et al (2007). Polymorphisms in DNA repair genes and risk of non-Hodgkin's lymphoma in New South Wales, Australia. Haematologica, 92, 1180-5. https://doi.org/10.3324/haematol.11324
  27. Shen M, Zheng T, Lan Q, et al (2006). Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut. Hum Genet, 119, 659-68. https://doi.org/10.1007/s00439-006-0177-2
  28. Smedby KE, Lindgren CM, Hjalgrim H, et al (2006). Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. Cancer Epidemiol Biomarkers Prev, 15, 258-65. https://doi.org/10.1158/1055-9965.EPI-05-0583
  29. Song B, Zhu JY, Liu J, et al (2008). Association of gene polymorphisms in the DNA repair gene XPD with risk of non-Hodgkin's lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 16, 97-100 (in Chinese).
  30. Sung P, Bailly V, Weber C, et al (1993). Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature, 365, 852-5. https://doi.org/10.1038/365852a0
  31. Weber CA, Salazar EP, Stewart SA, et al (1990). ERCC2: cDNA cloning and molecular characterization of a human nucleotide excision repair gene with high homology to yeast RAD3. Embo j, 9, 1437-47.
  32. Wood RD, Mitchell M, Sgouros J, et al (2001). Human DNA repair genes. Science, 291, 1284-9. https://doi.org/10.1126/science.1056154
  33. Worrillow L, Roman E, Adamson PJ, et al (2009). Polymorphisms in the nucleotide excision repair gene ERCC2/XPD and risk of non-Hodgkin lymphoma. Cancer Epidemiol, 33, 257-60. https://doi.org/10.1016/j.canep.2009.08.002
  34. Xin Y, Hao S, Lu J, et al (2014). Association of ERCC1 C8092A and ERCC2 Lys751Gln polymorphisms with the risk of glioma: a meta-analysis. PLoS One, 9, 95966. https://doi.org/10.1371/journal.pone.0095966
  35. Yan Y, Liang H, Light M, et al (2014). XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: a meta-analysis. Tumour Biol, 35, 1907-15. https://doi.org/10.1007/s13277-013-1256-3
  36. Yang F, Shi JY, Xu L, et al (2009). Genetic susceptibility of single nucleotide polymorphism in MGMT to non-Hodgkin lymphoma. Zhonghua Xue Ye Xue Za Zhi, 30, 622-5 (in Chinese).
  37. Yin QH, Liu C, Hu JB, et al (2013). XPD Lys751Gln and Asp312Asn polymorphisms and gastric cancer susceptibility: a meta-analysis of case-control studies. Asian Pac J Cancer Prev, 14, 231-6. https://doi.org/10.7314/APJCP.2013.14.1.231
  38. Zhu HL, Bao JM, Lin PX, et al (2014). XPD Lys751Gln and Asp312Asn polymorphisms and susceptibility to skin cancer: a meta-analysis of 17 case-control studies. Asian Pac J Cancer Prev, 15, 6619-25. https://doi.org/10.7314/APJCP.2014.15.16.6619

피인용 문헌

  1. Adult Non Hodgkin's Lymphoma Patients: Experience from a Tertiary Care Cancer Centre in North East India vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2879